1- (5- (7- (3- morpholinopropoxy)quinazolin- 4- ylthio)- (1,3,4)thiadiazol- 2- yl)- 3- p- tolylurea

an FLT3 inhibitor with antineoplastic activity; structure in first source

Also Known As:

1-(5-(7-(3-morpholinopropoxy)quinazolin-4-ylthio)-1,3,4-thiadiazol-2-yl)-3-p-toly-lurea; SKLB4771

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

1.	Psoriasis (Pustulosis Palmaris et Plantaris) 10/01/2014 - "SKLB4771, a potent and selective FLT3 inhibitor that we designed and synthesised, was used to treat cutaneous inflammation and psoriasis-like symptoms of disease in mice and almost completely cured the psoriasis-like disease without obvious toxicity. "
2.	Inflammation (Inflammations) 10/01/2014 - "SKLB4771, a potent and selective FLT3 inhibitor that we designed and synthesised, was used to treat cutaneous inflammation and psoriasis-like symptoms of disease in mice and almost completely cured the psoriasis-like disease without obvious toxicity. "